Pharmaceutical

Agenus gets grant for monoclonal antibodies targeting TIM-3 for treating subjects

Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.

May 3, 2024 - 00:00
Discover how Agenus Inc's groundbreaking patent for antibodies targeting TIM-3 is revolutionizing therapeutic antibody development. Explore the specific amino acid sequences and methods for efficient antibody production.
Read the original article

Tags:

Previous Article

Astellas Pharma gets grant for novel carbocyclic prolinamide derivatives for tre...

Next Article

Variety in building block softness makes for softer amorphous materials

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

U.S. backs study of safe injection sites, overdose prevention

U.S. backs study of safe injection sites, overdose prev...

May 9, 2023

STAT+: Illumina shareholders elect one Icahn ally to board, as company holds off broader challenge

STAT+: Illumina shareholders elect one Icahn ally to bo...

May 25, 2023

Cardurion closes $260m in Series B to develop cardiovascular pipeline

Cardurion closes $260m in Series B to develop cardiovas...

Jul 18, 2024